Bharat Immunologicals & Biologicals

Rs 28.43

Closing Price Date 02-Jul-2024

BSE 524663

Category Healthcare

SC NAME:

BH.IMMUN&BIO

Market Cap:

123

High / Low:

43.9 / 20.5

Stock P/E:

Book Value:

18.2

Dividend Yield:

0.00

ROCE:

-9.27

ROE:

-17.7

Face Value:

10.0

PEG Ratio:

EVEBITDA:

-11.2

Debt:

74.4

CMP / FCF:

-19.0

Debt to equity:

0.94

NP Ann:

-17.1

High price all time:

94.5

Piotroski score:

3.00

Graham Number:

No. Eq. Shares:

4.32

Net CF:

-3.36

Net profit:

-18.1

Price to book value:

1.56

Interest Coverage:

-2.26

Low price all time:

5.41

Reserves:

35.5

Industry PE:

26.7

Free Cash Flow:

10.9

Short Description

Bharat Immunologicals & Biologicals specializes in Pharmaceuticals within the Healthcare sector.

Long Description

Bharat Immunologicals & Biologicals, with Security Code 524663, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

Data Table

Quarterly Table

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2022-10-01	2022-12-31	-	-46.83	1.02	-1.08	-19.51	1.02	-0.37	-63.29
2022-07-01	2022-09-30	264.80	-30.83	267.99	-0.71	-6.51	3.20	-0.37	-39.59
2021-10-01	2021-12-31	174.31	-3.29	175.54	-0.08	-42.75	1.24	-0.41	-4.40
2021-07-01	2021-09-30	247.02	-93.61	249.19	-2.17	-31.80	2.17	-0.58	-45.60
2021-04-01	2021-06-30	142.15	19.27	144.65	0.45	-14.92	2.49	-0.59	0.73
2020-10-01	2020-12-31	251.99	-18.95	263.99	-0.44	-18.91	12.00	-0.59	-24.29
2020-07-01	2020-09-30	253.58	-38.66	254.96	-0.90	-31.38	1.38	-0.59	-55.85
2020-04-01	2020-06-30	191.53	-7.85	185.71	-0.18	-31.35	-5.82	-0.59	-11.04
2019-10-01	2019-12-31	284.84	-23.50	289.55	-0.54	-34.65	4.71	-0.57	-32.03
2019-07-01	2019-09-30	81.01	-56.59	82.76	-1.28	-20.05	1.75	-0.58	-78.23
2019-04-01	2019-06-30	70.00	-34.58	88.45	-0.80	-31.41	18.45	-2.04	-49.98
2019-01-01	2019-03-31	706.06	-22.42	726.97	-0.52	-51.00	20.91	0.33	-31.33
2018-10-01	2018-12-31	82.81	0.18	83.84	-0.58	-10.68	1.04	-1.03	0.22
2018-07-01	2018-09-30	46.72	-25.07	47.76	-	-21.20	1.04	-1.03	-37.01
2018-04-01	2018-06-30	0.87	-8.26	4.26	-	-16.23	3.40	-1.03	-12.42
2018-01-01	2018-03-31	216.81	-13.06	223.05	-	-7.88	6.24	-0.54	-40.98
2017-10-01	2017-12-31	44.65	4.98	48.21	0.12	-9.20	3.56	-0.72	3.82
2017-07-01	2017-09-30	53.05	-23.89	55.75	-	-9.40	2.70	-1.44	-22.68
2017-04-01	2017-06-30	33.47	-19.76	36.12	-	-7.10	2.66	-1.44	-19.16
2017-01-01	2017-03-31	613.42	40.82	615.58	-	-14.00	2.16	-0.12	59.88
2016-10-01	2016-12-31	240.43	14.32	-	-	-20.39	3.53	-0.19	15.67
2016-07-01	2016-09-30	110.08	15.47	-	-	-5.72	3.33	-1.10	24.69
2016-04-01	2016-06-30	277.93	-3.84	-	-	-13.26	4.33	-1.66	-5.31
2016-01-01	2016-03-31	589.90	9.63	-	-	-25.51	4.00	2.19	14.30
2015-10-01	2015-12-31	390.52	-6.86	-	-	-16.13	0.81	-2.89	-10.96
2015-07-01	2015-09-30	134.12	-24.77	-	-	-16.16	3.44	-2.90	-38.48
2015-04-01	2015-06-30	165.79	-31.49	-	-	-15.72	5.42	-2.87	-40.65
2014-07-01	2014-09-30	248.30	-8.37	-	-	-39.81	0.71	-2.12	-12.02
2014-04-01	2014-06-30	339.71	11.25	-	-	-10.39	0.71	-2.26	17.17
2014-01-01	2014-03-31	1,037.44	69.51	-	-	-35.32	7.90	-2.45	103.12
2013-10-01	2013-12-31	585.19	65.37	-	-	-16.57	9.45	-2.69	88.43
2013-07-01	2013-09-30	250.41	-29.73	-	-	-9.60	14.46	-2.57	-45.05
2013-04-01	2013-06-30	154.42	-16.25	-	-	-10.05	3.14	-2.48	-12.28

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2022-10-01	2022-12-31	-	-46.83	1.02	-1.08	-19.51	1.02	-0.37	-63.29
2022-07-01	2022-09-30	264.80	-30.83	267.99	-0.71	-6.51	3.20	-0.37	-39.59
2021-10-01	2021-12-31	174.31	-3.29	175.54	-0.08	-42.75	1.24	-0.41	-4.40
2021-07-01	2021-09-30	247.02	-93.61	249.19	-2.17	-31.80	2.17	-0.58	-45.60

Compounded Data

Standalone

Consolidated

Compounded Sales Growth
10 Years:	-13%
5 Years:	5%
3 Years:	-13%
TTM:	-90%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	-31%
TTM:	-42%

Stock Price CAGR
10 Years:	0%
5 Years:	31%
3 Years:	-26%
1 Year:	27%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	0%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	0%

Latest News

Bharat Biotech's Covaxin gets DCGI nod for booster dose
The DCGI has approved Bharat Biotech's Covaxin as a booster dose for those who have received two doses of Covishield or Covaxin vaccines.
Bharat Biotech's intranasal Covid vaccine gets DCGI nod for Phase III trials
The DCGI has given its nod to Bharat Biotech to conduct Phase III trials of its intranasal Covid vaccine, BBV154.
Bharat Biotech's Covaxin gets WHO approval for emergency use
The World Health Organization (WHO) has granted emergency use authorization to Bharat Biotech's Covaxin vaccine.
BIBCOL Announces the Launch of its New Vaccine Manufacturing Facility in Gujarat
The new facility will produce a range of vaccines, including those for Covid-19, rotavirus, and polio.
BIBCOL Partners with WHO to Expand Access to Vaccines in Developing Countries
The partnership will help to ensure that more people in developing countries have access to life-saving vaccines.
BIBCOL Reports Strong Financial Results for Q4 2022
The company's revenue and profits both increased significantly in the fourth quarter of 2022.